Jim Cramer Gives His Opinion On NeoGenomics, Yeti And More

On CNBC's "Mad Money Lightning Round," Jim Cramer said that NeoGenomics, Inc. NEO is a good spec, because early diagnostic of cancer is a holy grail.

Cramer is not a buyer of Yeti Holdings Inc YETI because it's already up 100% for the year.

Nutanix Inc NTNX is making a little comeback, but Cramer finds it too hard to recommend the stock.

Cadence Design Systems Inc CDNS is overvalued, said Cramer. He added that the company has never been able to put together a systematic year of great numbers. He is not a buyer.